Drugs / Naltrexone/bupropion
last change May 2022 re-read 2 minutes ago

Naltrexone/bupropion

Developed for
obesity disorder
Investigated by
Mayo Clinic

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03374956 Dec 2017 → May 2022 obesity disorder Mayo Clinic Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Naltrexone/bupropion ClinicalTrials.gov intervention name — accepted as the source's own label NCT03374956
Route Oral “32/360 mg oral daily” NCT03374956